-
公开(公告)号：US20210147801A1
公开(公告)日：2021-05-20
申请号：US16630098
申请日：2018-07-12
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , CENTRE HOSPITALER UNIVERSITAIRE DE NANTES
IPC分类号： C12N5/0783 , A61K35/17 , A61P37/06
摘要： A population of highly suppressive human CD8+CD45RClow/− Tregs is characterized by expressing Foxp3 and producing IFNγ, IL-10, IL-34 and TGFβ to mediate their suppressive activity. Accordingly, methods capable of increasing expansion and immunosuppressive capacity of such a population of CD8+CD45RClow/− Tregs are highly desirable for therapeutic purposes. Rapamycin has been shown to increase the expansion and immunosuppressive capacities of the population of CD8+CD45RClow/− Tregs. Accordingly, the method of increasing expansion and immunosuppressive capacity of a population of CD8+CD45RClow/− Tregs includes culturing the population of CD8+CD45RClow/− Tregs in presence of a rapamycin compound.
-
公开(公告)号：US20170226209A1
公开(公告)日：2017-08-10
申请号：US15500615
申请日：2015-07-31
发明人： Carole GUILLONNEAU , Ignacio ANEGON
IPC分类号： C07K16/28 , A61K38/13 , A61K31/436 , A61K31/664 , A61K39/395 , A61K45/06
CPC分类号： C07K16/289 , A61K31/436 , A61K31/664 , A61K38/13 , A61K39/3955 , A61K45/06 , A61K2039/507 , A61K2039/577
摘要： The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC+ cells. The invention relates to an isolated anti-CD45RC antibody for use in expanding and/or potentiating regulatory T cells.
-
公开(公告)号：US20220098264A1
公开(公告)日：2022-03-31
申请号：US17422556
申请日：2020-01-15
IPC分类号： C07K14/54 , C12N5/0786
摘要： Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3+ Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.
-
公开(公告)号：US20220033500A1
公开(公告)日：2022-02-03
申请号：US17277511
申请日：2019-09-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
发明人： Carole GUILLONNEAU , Ignacio ANEGON
摘要： Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
-
公开(公告)号：US20210163593A1
公开(公告)日：2021-06-03
申请号：US16772917
申请日：2018-12-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES , UNIVERSITÉ DE NANTES
发明人： Carole GUILLONNEAU , Ignacio ANEGON
摘要： Anti-CD45RC antibodies, for use in the treatment of monogenic diseases caused by genes not associated with immune function but whose deficiency is associated with inflammation and/or immune reactions (such as genes deficient in Duchenne muscular dystrophy (DMD), cystic fibrosis, lysosomal diseases and al-anti-trypsin deficiency); or caused by genes involved in the immune system and whose deficiency generates inflammation and/or autoimmune reactions (such as genes deficient in T-cell primary immunodeficiencies such as IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome), APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy), B cell primary immunodeficiencies, Muckle-Wells syndrome, mixed autoinflammatory and autoimmune syndrome, NLRP12-associated hereditary periodic fever syndrome, and tumor necrosis factor receptor 1 associated periodic syndrome).
-
公开(公告)号：US20210401940A1
公开(公告)日：2021-12-30
申请号：US17371646
申请日：2021-07-09
IPC分类号： A61K38/20 , A61K45/06 , A61K31/436 , G01N33/564 , G01N33/68
摘要： The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
7.发明申请公开(公告)号：US20190060405A1
公开(公告)日：2019-02-28
申请号：US16174837
申请日：2018-10-30
IPC分类号： A61K38/20 , G01N33/68 , G01N33/564 , A61K45/06 , A61K31/436
摘要： The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
8.发明申请公开(公告)号：US20170202921A1
公开(公告)日：2017-07-20
申请号：US15326515
申请日：2015-07-17
IPC分类号： A61K38/20 , A61K31/436 , A61K45/06
CPC分类号： A61K38/20 , A61K31/436 , A61K45/06 , G01N33/564 , G01N33/6893 , G01N2333/54 , G01N2800/245 , G01N2800/50 , A61K2300/00
摘要： The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
公开(公告)号：US20180015101A1
公开(公告)日：2018-01-18
申请号：US15521950
申请日：2015-10-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , ONIRIS
发明人： Ignacio ANEGON , Philippe BLANCOU , Thomas SIMON , Julien POGU
IPC分类号： A61K31/555 , A61K39/04 , C12N5/078 , A61K39/00
CPC分类号： A61K31/555 , A61K31/409 , A61K39/0008 , A61K39/001 , A61K39/04 , A61K45/06 , A61K2039/5154 , A61K2039/54 , A61K2039/55511 , A61K2039/577 , A61K2039/58 , C12N5/0634 , C12N2501/71 , A61K2300/00
摘要： The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase-1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance.
-
公开(公告)号：US20170173125A1
公开(公告)日：2017-06-22
申请号：US15300331
申请日：2015-04-01
IPC分类号： A61K39/00 , G01N33/569 , A61K35/17 , C07K14/74 , C12N5/0783
CPC分类号： A61K39/001 , A61K35/17 , A61K38/00 , A61K2035/122 , A61K2039/577 , C07K7/06 , C07K7/08 , C07K14/70539 , C12N5/0637 , C12N2501/998 , C12N2502/1121 , G01N33/505 , G01N33/56972 , G01N2333/70517 , G01N2333/70589 , G01N2800/245 , G01N2800/52
摘要： The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid sequence: SDVGEYR (SEQ ID NO: 1) or a function-conservative variant thereof for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.032 秒)
